In people with obesity and diabetes, dapagliflozin plus exenatide reduced right caudate activation during food anticipation versus placebo after 16 weeks.
In plain wordsIn people with obesity and diabetes, dapagliflozin plus exenatide reduced right caudate activation during food anticipation versus placebo after 16 weeks.
- Peptide
- Exenatide (exendin-4)
- Outcome
- DecreaseRight caudate activation during food anticipation
- Study
n: not reported in source
- Comparator
- Double placebo
- Outcome group
- Receptor activity and mechanism · Nervous system and cognition
Source sentences
Dapagliflozin plus exenatide reduced activation in right caudate nucleus and amygdala to the anticipation of food, and decreased activation in the right amygdala in response to food receipt after 16 weeks.
3 context sentences(design, population, supporting numbers)
As part of a larger study, this was a 16 week, double-blind, randomized, placebo-controlled trial.
Subjects with obesity and type 2 diabetes were randomized (1:1:1:1) to dapagliflozin 10 mg with exenatide-matched placebo, exenatide twice-daily 10 μg with dapagliflozin-matched placebo, dapagliflozin plus exenatide, or double placebo.
Using functional magnetic resonance imaging, the effects of treatments on brain responses to the anticipation of food and food receipt were assessed after 10 days and 16 weeks.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).